| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLT1 |
| Uniprot No | P17948 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-756aa |
| 氨基酸序列 | SKLKDPELSLKGTQHIMQAGQTLHLQCRGEAAHKWSLPEMVSKESERLSITKSACGRNGKQFCSTLTLNTAQANHTGFYSCKYLAVPTSKKKETESAIYIFISDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVQISTPRPVKLLRGHTLVLNCTATTPLNTRVQMTWSYPDEKNKRASVRRRIDQSNSHANIFYSVLTIDKMQNKDKGLYTCRVRSGPSFKSVNTSVHIYDKAFITVKHRKQQVLETVAGKRSYRLSMKVKAFPSPEVVWLKDGLPATEKSARYLTRGYSLIIKDVTEEDAGNYTILLSIKQSNVFKNLTATLIVNVKPQIYEKAVSSFPDPALYPLGSRQILTCTAYGIPQPTIKWFWHPCNHNHSEARCDFCSNNEESFILDADSNMGNRIESITQRMAIIEGKNKMASTLVVADSRISGIYICIASNKVGTVGRNISFYITDVPNGFHVNLEKMPTEGEDLKLSCTVNKFLYRDVTWILLRTVNNRTMHYSISKQKMAITKEHSITLNLTIMNVSLQDSGTYACRARNVYTGEEILQKKEITIRDQEAPYLLRNLSDHTVAISSSTTLDCHANGVPEPQITWFKNNHKIQQEPGIILGPGSSTLFIERVTEEDEGVYHCKATNQKGSVESSAYLTVQGTSDKSN |
| 预测分子量 | 86.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FLT1重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *Soluble FLT1 Gene Therapy Alleviates Brain Arteriovenous Malformation Severity*
**作者**: Li, X., et al.
**摘要**: 该研究通过腺相关病毒(AAV)递送可溶性FLT1重组蛋白(sFLT1)至小鼠模型，发现其显著减少脑动静脉畸形(BAVM)的血管异常增生。sFLT1通过竞争性结合VEGF，抑制异常血管生成信号通路，为BAVM治疗提供潜在策略。
---
2. **文献名称**: *Recombinant FLT1 Extracellular Domain Expression in CHO Cells and Its Anti-angiogenic Activity*
**作者**: Chen, Y., et al.
**摘要**: 研究者利用中国仓鼠卵巢(CHO)细胞系统高效表达FLT1胞外域重组蛋白，并验证其抑制血管内皮细胞迁移和管状结构形成的能力。该蛋白通过阻断VEGF-A与膜受体结合，显著抑制体外血管生成。
---
3. **文献名称**: *Structural Insights into FLT1 Receptor Activation by VEGF*
**作者**: Park, J.H., et al.
**摘要**: 通过X射线晶体学解析FLT1与VEGF复合物的三维结构，揭示VEGF结合诱导的受体二聚化机制。研究阐明了FLT1特异性识别配体的结构基础，为设计靶向FLT1的血管疾病药物提供理论依据。
---
注：以上文献为示例，实际引用需根据具体研究内容核实。建议通过PubMed、Web of Science等平台以“FLT1 recombinant protein”或“sFLT1 therapy”为关键词检索最新文献。
**Background of FLT1 Recombinant Protein**
FLT1 (Fms-like tyrosine kinase 1), also known as vascular endothelial growth factor receptor 1 (VEGFR-1), is a transmembrane receptor tyrosine kinase that plays a critical role in regulating angiogenesis and vascular development. It is part of the VEGF signaling pathway, binding ligands such as VEGF-A, VEGF-B, and placental growth factor (PlGF). Unlike its homolog VEGFR-2 (KDR/FLK1), which primarily drives endothelial cell proliferation and permeability, FLT1 has dual roles: it modulates angiogenesis by acting as a decoy receptor to sequester VEGF ligands, thereby fine-tuning signaling through VEGFR-2. and it directly mediates cellular responses in specific contexts, such as monocyte migration and vascular remodeling.
FLT1 recombinant protein is engineered in vitro using expression systems like mammalian cells (e.g., HEK293 or CHO cells) or insect cells to produce soluble, functional forms of the receptor. These proteins typically include the extracellular ligand-binding domain (Ig-like domains 1-3), enabling interaction with VEGF family ligands. Recombinant FLT1 is widely utilized in research to study angiogenesis mechanisms, screen anti-angiogenic drugs, or neutralize excess VEGF in pathological conditions like cancer or age-related macular degeneration.
Clinically, FLT1’s role in preeclampsia has drawn significant attention, as elevated soluble FLT1 (sFLT1) levels contribute to placental vascular dysfunction. Recombinant FLT1 variants are explored as therapeutic tools to counteract VEGF-driven pathologies or as biomarkers. Its structural and functional complexity makes it a key target in understanding vascular biology and developing targeted therapies.
×
